Fuzica-M Cream is a topical medication combining Mometasone furoate (0.1% w/w), a potent corticosteroid, with Fusidic Acid (2% w/w), a bacteriostatic antibiotic, designed to treat inflammatory skin conditions complicated by bacterial infections. Mometasone acts by reducing inflammation, redness, and itching through its anti-inflammatory, antipruritic, and vasoconstrictive properties, while Fusidic Acid effectively inhibits bacterial protein synthesis, targeting Gram-positive bacteria such as Staphylococcus aureus. This dual-action formulation is particularly useful in managing infected eczema, dermatitis, and other inflammatory dermatoses where secondary bacterial infection is present or suspected. Fuzica-M Cream should be applied topically in a thin layer to the affected area once or twice daily as directed by a healthcare professional. It is important to avoid prolonged use to minimize potential side effects associated with corticosteroids, such as skin thinning or systemic absorption. The cream is not recommended for use on fungal or viral skin infections unless combined with appropriate therapy. Patients should consult a physician before use, especially if pregnant, breastfeeding, or treating children. Proper hygiene and adherence to prescribed duration enhance treatment efficacy and reduce the risk of resistance or adverse effects.